

Docket No.: PF-0417-2 DIV

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on \_\_\_\_\_\_ June 07, 2001\_\_\_\_\_\_.

Ry: Emmo 7. Duan 01

rinted: Emma Febre-Durrell



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Application of: Bandman et al.

JUN 2 5 2001

Title: VESICLE TRAFFICKING PROTEINS

TECH CENTER 1600/2900

Serial No.:

09/556,178

Filing Date:

April 20, 2000

Examiner:

Steadman, D.

Group Art Unit:

1652

Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121

Sir:

This is in response to the Restriction Requirement and Request for Election mailed May 11, 2001, setting a one month term for response.

In the Restriction Requirement, the Examiner requested Applicants to elect one of the following inventions:

Group I (claims 1, 2, 16, and 17) drawn to vesicle trafficking protein (VTP) polypeptides and pharmaceutical compositions thereof.

Group II (claims 3-9, 11, and 12) drawn to polynucleotides encoding, host cells expressing, and a method for producing a VTP polypeptide.

Group III (claim 10) drawn to an isolated antibody.

Group IV (claims 13-15) drawn to methods for detecting a target polynucleotide in a sample.

Group V (claims 18-19) drawn to methods for screening a compound for effectiveness as an agonist or as an antagonist.

Group VI (claim 20) drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide.